Whitehawk Therapeutics (NASDAQ:WHWK) Announces Earnings Results

Whitehawk Therapeutics (NASDAQ:WHWK) announced its quarterly earnings data on Thursday. The company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.25, Zacks reports. Whitehawk Therapeutics had a negative return on equity of 69.28% and a net margin of 99.42%.

Whitehawk Therapeutics Trading Down 1.4%

WHWK traded down $0.03 during midday trading on Friday, hitting $2.07. 255,951 shares of the company’s stock traded hands, compared to its average volume of 5,212,431. The stock has a market capitalization of $97.55 million, a P/E ratio of 14.79 and a beta of 0.58. The company’s fifty day moving average price is $2.08. Whitehawk Therapeutics has a one year low of $1.39 and a one year high of $3.81.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the stock. Wall Street Zen lowered shares of Whitehawk Therapeutics to a “strong sell” rating in a research report on Saturday, November 1st. Weiss Ratings reiterated a “sell (e+)” rating on shares of Whitehawk Therapeutics in a research report on Wednesday, October 8th. Finally, Zacks Research raised shares of Whitehawk Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, October 7th. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Reduce”.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Whitehawk Therapeutics stock. Vanguard Group Inc. acquired a new stake in Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 1,342,907 shares of the company’s stock, valued at approximately $2,552,000. Vanguard Group Inc. owned about 2.85% of Whitehawk Therapeutics at the end of the most recent quarter. 52.08% of the stock is currently owned by institutional investors and hedge funds.

Whitehawk Therapeutics Company Profile

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway.